prof. dr. H.J. (Hiddo) Lambers Heerspink

Clinical Pharmacologist


  1. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels

    Gant, C. M., Laverman, G. D., Vogt, L., Slagman, M. C. J., Heerspink, H. J. L., Waanders, F., Hemmelder, M. H., Navis, G. & Holland Nephrology Study (HONEST) Network 20-Dec-2017 In : Bmc nephrology. 18, 8 p., 370

    Research output: Contribution to journalArticle

  2. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension

    Lindhardt, M., Persson, F., Oxlund, C., Jacobsen, I. A., Zürbig, P., Mischak, H., Rossing, P. & Heerspink, H. J. L. Feb-2018 In : Nephrology, Dialysis, Transplantation. 33, 2, p. 296-303 8 p.

    Research output: Contribution to journalArticle

  3. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

    Petrykiv, S., Laverman, G. D., de Zeeuw, D. & Heerspink, H. J. L. Jan-2018 In : Diabetes obesity & metabolism. 20, 1, p. 224-227 4 p.

    Research output: Contribution to journalArticle

View all (203) »

View graph of relations

ID: 208085